Kastelein Johannes Jacob Pieter 4
4 · NewAmsterdam Pharma Co N.V. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
NewAmsterdam (NAMS) CSO Kastelein Exercises Options, Sells 300K Shares
What Happened
Kastelein Johannes Jacob Pieter, Chief Scientific Officer and a director of NewAmsterdam Pharma Co. N.V., exercised stock options and immediately sold the resulting shares in open-market transactions. He exercised options to acquire 104,467 shares (Mar 5), 94,124 shares (Mar 6) and 101,409 shares (Mar 9), then sold those same amounts at weighted-average prices of $30.30, $30.32 and $30.29, respectively. The three sales produced proceeds of approximately $3.165M, $2.854M and $3.072M — about $9.09M in total for 300,000 shares.
Key Details
- Transaction dates and prices:
- Mar 5, 2026: exercised 104,467 shares; sold 104,467 shares at a weighted avg $30.30 (sales ranged $30.00–$30.55). Proceeds ≈ $3,165,350. (F1, F3)
- Mar 6, 2026: exercised 94,124 shares; sold 94,124 shares at a weighted avg $30.32 (sales ranged $30.00–$30.42). Proceeds ≈ $2,853,840. (F1, F4)
- Mar 9, 2026: exercised 101,409 shares; sold 101,409 shares at a weighted avg $30.29 (sales ranged $30.00–$30.80). Proceeds ≈ $3,071,679. (F1, F5)
- Exercise price: EUR 1.16392 per share (F1).
- Holdings/control: The ordinary shares are held by Futurum B.V. for the benefit of the Reporting Person; he exercises sole voting and investment control (F2, F7). Upon exercise, shares were issued to Futurum pursuant to an agreement among Futurum, PoolCo and the issuer (F7).
- Option history/vesting: Options were granted/replaced on Nov 22, 2022 (replacement of a July 6, 2021 option); a large portion vested immediately and the remainder vests on a schedule subject to continued service (F6).
- Shares owned after the transactions: Not specified in the provided Form 4 extract.
- Filing timeliness: The Form 4 was filed on Mar 9, 2026. Trades on Mar 5 and Mar 6 were reported on Mar 9 (more than two business days after those trades) and thus were filed late; the Mar 9 trades were filed same day.
Context
- These transactions are exercises of options followed by immediate open-market sales (a common cashless exercise/monetization). The Form 4 shows the option exercise prices and that the shares were issued to an entity (Futurum) controlled by the Reporting Person; it does not state the insider’s motive.
- For retail investors: purchases are often viewed as stronger signals than sales. These filings document monetization of vested options rather than a typical open-market purchase of new shares.
Insider Transaction Report
Form 4
Kastelein Johannes Jacob Pieter
DirectorChief Scientific Officer
Transactions
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-05+104,467→ 173,769 total(indirect: See footnote) - Sale
Ordinary Shares
[F3][F2]2026-03-05$30.30/sh−104,467$3,165,350→ 69,302 total(indirect: See footnote) - Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-06+94,124→ 163,426 total(indirect: See footnote) - Sale
Ordinary Shares
[F4][F2]2026-03-06$30.32/sh−94,124$2,853,840→ 69,302 total(indirect: See footnote) - Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-09+101,409→ 170,711 total(indirect: See footnote) - Sale
Ordinary Shares
[F5][F2]2026-03-09$30.29/sh−101,409$3,071,679→ 69,302 total(indirect: See footnote) - Exercise/Conversion
Option (right to buy)
[F1][F6][F7]2026-03-05−104,467→ 715,762 total(indirect: See footnote)Exp: 2031-07-06→ Ordinary Shares (104,467 underlying) - Exercise/Conversion
Option (right to buy)
[F1][F6][F7]2026-03-06−94,124→ 621,638 total(indirect: See footnote)Exp: 2031-07-06→ Ordinary Shares (94,124 underlying) - Exercise/Conversion
Option (right to buy)
[F1][F6][F7]2026-03-09−101,409→ 520,229 total(indirect: See footnote)Exp: 2031-07-06→ Ordinary Shares (101,409 underlying)
Footnotes (7)
- [F1]The exercise price of the option is EUR 1.16392.
- [F2]The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F6]The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- [F7]The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.
Signature
/s/ Louise Kooij by Power of Attorney for Johannes Jacob Pieter Kastelein|2026-03-09